Chugai Seiyaku Kabushiki Kaisha

Galderma Holding Sa

Keiko Hirokawa

Ryosuke Mihara

Hidetomo Kitamura

Yoshinobu Higuchi

Yuki Iwayanagi

Yumi Yamamoto

Akihisa Kaneko

Tomohisa Saito

Hiroaki Matsushita

Nabil Kerrouche

In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient

Disclosed herein are methods for selectively treating atopic dermatitis (AD) in a subject having skin excoriations, pharmaceutical compositions for use in the treatment of atopic dermatitis in a subject having skin excoriations, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of atopic dermatitis in a subject having skin excoriations, and methods of identifying a subject having atopic dermatitis that is likely to respond to nemolizumab treatment or an equivalent thereof.

Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Growing community of inventors

Tokyo, Japan

Keiko Hirokawa